Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy

Anup Kumar, Srinivas Samavedi, Vladimir Mouraviev, Anthony S. Bates, Rafael F. Coelho, Bernardo Rocco, Vipul R. Patel

Research output: Contribution to journalArticle

Abstract

Our aim was to evaluate factors associated with persistently elevated prostate-specific antigen (PSA) and biochemical recurrence following robotic-assisted radical prostatectomy (RARP). The study population (N = 5300) consisted of consecutive patients who underwent RARP for localized prostate cancer by a single surgeon (VP) from January 2008 through July 2013. A query of our Institutional Review Board-approved registry identified 162 men with persistently elevated PSA (group A), defined as PSA level ≥0.1 ng/ml at 6 weeks after surgery, who were compared with rest of the cohort group having undetectable PSA, group B (10 ng/ml (p = 0.01), Gleason Score ≥8 (p = 0.001) and clinical stage(p = 0.001)]; postoperative [pathologic stage (p = 0.001), extraprostatic extension (EPE, p = 0.01), lymph node positivity (p = 0.001), positive surgical margin (PSM, p = 0.02), Gleason score (p = 0.01) and tumor volume percent (p <0.001)]. The mean follow-up was 38.1 months. The BCR was significantly higher in group A as compared to group B(52.47 vs 7.9 %) respectively; p = 0.01). The mean time to BCR was significantly lesser in group A as compared to group B(8.9 vs 21.1 months respectively; p = 0.01). The BCR-free survival rates at 1 year and 3 years were significantly lower statistically in the persistent PSA group in comparison to other groups (69.7 vs 97.3 % and 48.5 vs 92.1 %, respectively; p = 0.01). On multivariate logistic regression analysis in patients with persistent PSA on follow-up, preoperative PSA >10 ng/ml, postoperative Gleason score ≥8, postoperative stage ≥pT3, positive pelvic lymph nodes, PSM >3 mm and post-RARP PSA doubling time (DT)

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalJournal of Robotic Surgery
DOIs
Publication statusAccepted/In press - May 31 2016

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Neoplasm Grading
Robotics
Lymph Nodes
Research Ethics Committees
Tumor Burden
Registries
Prostatic Neoplasms
Recurrence
Population

Keywords

  • Oncologic outcome
  • Predictive factors
  • Prostate-specific antigen
  • Prostatectomy
  • Robotic-assisted radical prostatectomy

ASJC Scopus subject areas

  • Surgery
  • Health Informatics

Cite this

Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy. / Kumar, Anup; Samavedi, Srinivas; Mouraviev, Vladimir; Bates, Anthony S.; Coelho, Rafael F.; Rocco, Bernardo; Patel, Vipul R.

In: Journal of Robotic Surgery, 31.05.2016, p. 1-9.

Research output: Contribution to journalArticle

Kumar, Anup ; Samavedi, Srinivas ; Mouraviev, Vladimir ; Bates, Anthony S. ; Coelho, Rafael F. ; Rocco, Bernardo ; Patel, Vipul R. / Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy. In: Journal of Robotic Surgery. 2016 ; pp. 1-9.
@article{77c6cfeb90034e5cad933eff44d7a41a,
title = "Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy",
abstract = "Our aim was to evaluate factors associated with persistently elevated prostate-specific antigen (PSA) and biochemical recurrence following robotic-assisted radical prostatectomy (RARP). The study population (N = 5300) consisted of consecutive patients who underwent RARP for localized prostate cancer by a single surgeon (VP) from January 2008 through July 2013. A query of our Institutional Review Board-approved registry identified 162 men with persistently elevated PSA (group A), defined as PSA level ≥0.1 ng/ml at 6 weeks after surgery, who were compared with rest of the cohort group having undetectable PSA, group B (10 ng/ml (p = 0.01), Gleason Score ≥8 (p = 0.001) and clinical stage(p = 0.001)]; postoperative [pathologic stage (p = 0.001), extraprostatic extension (EPE, p = 0.01), lymph node positivity (p = 0.001), positive surgical margin (PSM, p = 0.02), Gleason score (p = 0.01) and tumor volume percent (p <0.001)]. The mean follow-up was 38.1 months. The BCR was significantly higher in group A as compared to group B(52.47 vs 7.9 {\%}) respectively; p = 0.01). The mean time to BCR was significantly lesser in group A as compared to group B(8.9 vs 21.1 months respectively; p = 0.01). The BCR-free survival rates at 1 year and 3 years were significantly lower statistically in the persistent PSA group in comparison to other groups (69.7 vs 97.3 {\%} and 48.5 vs 92.1 {\%}, respectively; p = 0.01). On multivariate logistic regression analysis in patients with persistent PSA on follow-up, preoperative PSA >10 ng/ml, postoperative Gleason score ≥8, postoperative stage ≥pT3, positive pelvic lymph nodes, PSM >3 mm and post-RARP PSA doubling time (DT)",
keywords = "Oncologic outcome, Predictive factors, Prostate-specific antigen, Prostatectomy, Robotic-assisted radical prostatectomy",
author = "Anup Kumar and Srinivas Samavedi and Vladimir Mouraviev and Bates, {Anthony S.} and Coelho, {Rafael F.} and Bernardo Rocco and Patel, {Vipul R.}",
year = "2016",
month = "5",
day = "31",
doi = "10.1007/s11701-016-0606-8",
language = "English",
pages = "1--9",
journal = "Journal of Robotic Surgery",
issn = "1863-2483",
publisher = "Springer London",

}

TY - JOUR

T1 - Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy

AU - Kumar, Anup

AU - Samavedi, Srinivas

AU - Mouraviev, Vladimir

AU - Bates, Anthony S.

AU - Coelho, Rafael F.

AU - Rocco, Bernardo

AU - Patel, Vipul R.

PY - 2016/5/31

Y1 - 2016/5/31

N2 - Our aim was to evaluate factors associated with persistently elevated prostate-specific antigen (PSA) and biochemical recurrence following robotic-assisted radical prostatectomy (RARP). The study population (N = 5300) consisted of consecutive patients who underwent RARP for localized prostate cancer by a single surgeon (VP) from January 2008 through July 2013. A query of our Institutional Review Board-approved registry identified 162 men with persistently elevated PSA (group A), defined as PSA level ≥0.1 ng/ml at 6 weeks after surgery, who were compared with rest of the cohort group having undetectable PSA, group B (10 ng/ml (p = 0.01), Gleason Score ≥8 (p = 0.001) and clinical stage(p = 0.001)]; postoperative [pathologic stage (p = 0.001), extraprostatic extension (EPE, p = 0.01), lymph node positivity (p = 0.001), positive surgical margin (PSM, p = 0.02), Gleason score (p = 0.01) and tumor volume percent (p <0.001)]. The mean follow-up was 38.1 months. The BCR was significantly higher in group A as compared to group B(52.47 vs 7.9 %) respectively; p = 0.01). The mean time to BCR was significantly lesser in group A as compared to group B(8.9 vs 21.1 months respectively; p = 0.01). The BCR-free survival rates at 1 year and 3 years were significantly lower statistically in the persistent PSA group in comparison to other groups (69.7 vs 97.3 % and 48.5 vs 92.1 %, respectively; p = 0.01). On multivariate logistic regression analysis in patients with persistent PSA on follow-up, preoperative PSA >10 ng/ml, postoperative Gleason score ≥8, postoperative stage ≥pT3, positive pelvic lymph nodes, PSM >3 mm and post-RARP PSA doubling time (DT)

AB - Our aim was to evaluate factors associated with persistently elevated prostate-specific antigen (PSA) and biochemical recurrence following robotic-assisted radical prostatectomy (RARP). The study population (N = 5300) consisted of consecutive patients who underwent RARP for localized prostate cancer by a single surgeon (VP) from January 2008 through July 2013. A query of our Institutional Review Board-approved registry identified 162 men with persistently elevated PSA (group A), defined as PSA level ≥0.1 ng/ml at 6 weeks after surgery, who were compared with rest of the cohort group having undetectable PSA, group B (10 ng/ml (p = 0.01), Gleason Score ≥8 (p = 0.001) and clinical stage(p = 0.001)]; postoperative [pathologic stage (p = 0.001), extraprostatic extension (EPE, p = 0.01), lymph node positivity (p = 0.001), positive surgical margin (PSM, p = 0.02), Gleason score (p = 0.01) and tumor volume percent (p <0.001)]. The mean follow-up was 38.1 months. The BCR was significantly higher in group A as compared to group B(52.47 vs 7.9 %) respectively; p = 0.01). The mean time to BCR was significantly lesser in group A as compared to group B(8.9 vs 21.1 months respectively; p = 0.01). The BCR-free survival rates at 1 year and 3 years were significantly lower statistically in the persistent PSA group in comparison to other groups (69.7 vs 97.3 % and 48.5 vs 92.1 %, respectively; p = 0.01). On multivariate logistic regression analysis in patients with persistent PSA on follow-up, preoperative PSA >10 ng/ml, postoperative Gleason score ≥8, postoperative stage ≥pT3, positive pelvic lymph nodes, PSM >3 mm and post-RARP PSA doubling time (DT)

KW - Oncologic outcome

KW - Predictive factors

KW - Prostate-specific antigen

KW - Prostatectomy

KW - Robotic-assisted radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=84973120846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973120846&partnerID=8YFLogxK

U2 - 10.1007/s11701-016-0606-8

DO - 10.1007/s11701-016-0606-8

M3 - Article

AN - SCOPUS:84973120846

SP - 1

EP - 9

JO - Journal of Robotic Surgery

JF - Journal of Robotic Surgery

SN - 1863-2483

ER -